Aurinia Pharmaceuticals (NASDAQ:AUPH) Rating Increased to Strong-Buy at StockNews.com

StockNews.com upgraded shares of Aurinia Pharmaceuticals (NASDAQ:AUPH - Free Report) TSE: AUP from a buy rating to a strong-buy rating in a research note released on Thursday morning.

Aurinia Pharmaceuticals Trading Down 3.9 %

Shares of Aurinia Pharmaceuticals stock traded down $0.33 during trading on Thursday, reaching $7.97. 532,513 shares of the stock were exchanged, compared to its average volume of 1,344,581. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -53.03 and a beta of 1.26. Aurinia Pharmaceuticals has a 1 year low of $4.71 and a 1 year high of $10.67. The stock's fifty day moving average is $8.09 and its 200 day moving average is $8.05.

Insider Buying and Selling

In other news, insider Greg Keenan sold 8,305 shares of the business's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $8.23, for a total value of $68,350.15. Following the sale, the insider now directly owns 153,484 shares of the company's stock, valued at $1,263,173.32. The trade was a 5.13 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Matthew Maxwell Donley sold 65,902 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $527,216.00. Following the completion of the sale, the chief operating officer now owns 739,456 shares in the company, valued at $5,915,648. The trade was a 8.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 343,898 shares of company stock valued at $2,753,094 over the last three months. Corporate insiders own 4.30% of the company's stock.

Remove Ads

Hedge Funds Weigh In On Aurinia Pharmaceuticals

A number of hedge funds have recently bought and sold shares of AUPH. Wellington Management Group LLP purchased a new position in Aurinia Pharmaceuticals in the fourth quarter worth about $546,000. GF Fund Management CO. LTD. bought a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter valued at approximately $27,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Aurinia Pharmaceuticals by 21.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 363,674 shares of the biotechnology company's stock worth $3,266,000 after acquiring an additional 65,220 shares during the last quarter. Woodline Partners LP lifted its position in Aurinia Pharmaceuticals by 69.7% in the 4th quarter. Woodline Partners LP now owns 849,477 shares of the biotechnology company's stock valued at $7,628,000 after acquiring an additional 348,983 shares in the last quarter. Finally, Vermillion & White Wealth Management Group LLC purchased a new stake in Aurinia Pharmaceuticals during the 4th quarter valued at $31,000. Institutional investors own 36.83% of the company's stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.